Cargando…
Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and monkeypox virus (MPXV) severely threaten human health; however, currently, no vaccine can prevent a co-infection with both viruses. METHODS: Five antigens were selected to predict dominant T and B cell epitopes screened for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832108/ https://www.ncbi.nlm.nih.gov/pubmed/36652758 http://dx.doi.org/10.1016/j.intimp.2023.109728 |
_version_ | 1784867992292556800 |
---|---|
author | Jiang, Fan Liu, Yinping Xue, Yong Cheng, Peng Wang, Jie Lian, Jianqi Gong, Wenping |
author_facet | Jiang, Fan Liu, Yinping Xue, Yong Cheng, Peng Wang, Jie Lian, Jianqi Gong, Wenping |
author_sort | Jiang, Fan |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and monkeypox virus (MPXV) severely threaten human health; however, currently, no vaccine can prevent a co-infection with both viruses. METHODS: Five antigens were selected to predict dominant T and B cell epitopes screened for immunogenicity, antigenicity, toxicity, and sensitization. After screening, all antigens joined in the construction of a novel multiepitope vaccine. The physicochemical and immunological characteristics, and secondary and tertiary structures of the vaccine were predicted and analyzed using bio- and immunoinformatics. Finally, codon optimization and cloning in-silico were performed. RESULTS: A new multiepitope vaccine, named S7M8, was constructed based on four helper T lymphocyte (HTL) epitopes, six cytotoxic T lymphocyte (CTL) epitopes, five B cell epitopes, as well as Toll-like receptor (TLR) agonists. The antigenicity and immunogenicity scores of the S7M8 vaccine were 0.907374 and 0.6552, respectively. The S7M8 vaccine was comprised of 26.96% α-helices, the optimized Z-value of the tertiary structure was −5.92, and the favored area after majorization in the Ramachandran plot was 84.54%. Molecular docking showed that the S7M8 vaccine could tightly bind to TLR2 (−1100.6 kcal/mol) and TLR4 (−950.3 kcal/mol). In addition, the immune stimulation prediction indicated that the S7M8 vaccine could activate T and B lymphocytes to produce high levels of Th1 cytokines and antibodies. CONCLUSION: S7M8 is a promising biomarker with good antigenicity, immunogenicity, non-toxicity, and non-sensitization. The S7M8 vaccine can trigger significantly high levels of Th1 cytokines and antibodies and may be a potentially powerful tool in preventing SARS-CoV-2 and MPXV. |
format | Online Article Text |
id | pubmed-9832108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98321082023-01-11 Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis Jiang, Fan Liu, Yinping Xue, Yong Cheng, Peng Wang, Jie Lian, Jianqi Gong, Wenping Int Immunopharmacol Article BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and monkeypox virus (MPXV) severely threaten human health; however, currently, no vaccine can prevent a co-infection with both viruses. METHODS: Five antigens were selected to predict dominant T and B cell epitopes screened for immunogenicity, antigenicity, toxicity, and sensitization. After screening, all antigens joined in the construction of a novel multiepitope vaccine. The physicochemical and immunological characteristics, and secondary and tertiary structures of the vaccine were predicted and analyzed using bio- and immunoinformatics. Finally, codon optimization and cloning in-silico were performed. RESULTS: A new multiepitope vaccine, named S7M8, was constructed based on four helper T lymphocyte (HTL) epitopes, six cytotoxic T lymphocyte (CTL) epitopes, five B cell epitopes, as well as Toll-like receptor (TLR) agonists. The antigenicity and immunogenicity scores of the S7M8 vaccine were 0.907374 and 0.6552, respectively. The S7M8 vaccine was comprised of 26.96% α-helices, the optimized Z-value of the tertiary structure was −5.92, and the favored area after majorization in the Ramachandran plot was 84.54%. Molecular docking showed that the S7M8 vaccine could tightly bind to TLR2 (−1100.6 kcal/mol) and TLR4 (−950.3 kcal/mol). In addition, the immune stimulation prediction indicated that the S7M8 vaccine could activate T and B lymphocytes to produce high levels of Th1 cytokines and antibodies. CONCLUSION: S7M8 is a promising biomarker with good antigenicity, immunogenicity, non-toxicity, and non-sensitization. The S7M8 vaccine can trigger significantly high levels of Th1 cytokines and antibodies and may be a potentially powerful tool in preventing SARS-CoV-2 and MPXV. Elsevier B.V. 2023-02 2023-01-11 /pmc/articles/PMC9832108/ /pubmed/36652758 http://dx.doi.org/10.1016/j.intimp.2023.109728 Text en © 2023 Elsevier B.V. All rights reserved. Elsevier has created a Monkeypox Information Center (https://www.elsevier.com/connect/monkeypox-information-center) in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active. |
spellingShingle | Article Jiang, Fan Liu, Yinping Xue, Yong Cheng, Peng Wang, Jie Lian, Jianqi Gong, Wenping Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis |
title | Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis |
title_full | Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis |
title_fullStr | Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis |
title_full_unstemmed | Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis |
title_short | Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis |
title_sort | developing a multiepitope vaccine for the prevention of sars-cov-2 and monkeypox virus co-infection: a reverse vaccinology analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832108/ https://www.ncbi.nlm.nih.gov/pubmed/36652758 http://dx.doi.org/10.1016/j.intimp.2023.109728 |
work_keys_str_mv | AT jiangfan developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis AT liuyinping developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis AT xueyong developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis AT chengpeng developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis AT wangjie developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis AT lianjianqi developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis AT gongwenping developingamultiepitopevaccineforthepreventionofsarscov2andmonkeypoxviruscoinfectionareversevaccinologyanalysis |